8-K: electroCore Reports Strong Q3 2025 Revenue Growth

electroCore, Inc. announced record third-quarter 2025 financial results with net sales up 33% year-over-year and increased full-year revenue guidance.

Summary

• Net sales for Q3 2025 reached $8.7 million, a 33% increase compared to $6.6 million in Q3 2024.
• Year-to-date net sales were $22.8 million, up 26% from the first nine months of 2024.
• Gross profit for Q3 2025 was $7.5 million, with an 86% gross margin, up from $5.5 million and 84% gross margin in Q3 2024.
• Net loss for Q3 2025 increased to $3.4 million ($0.40 per share) from $2.5 million ($0.31 per share) in Q3 2024.
• Adjusted EBITDA net loss for Q3 2025 was $2.0 million, a slight improvement from $2.1 million in Q3 2024.
• Total Cash (cash, cash equivalents, restricted cash, and marketable securities) stood at $13.2 million as of September 30, 2025, up from $12.2 million at December 31, 2024.
• The company increased its full-year 2025 revenue guidance to $31.5 million to $32.5 million.
• Prescription device sales increased 19% to $6.81 million in Q3 2025, while Health and Wellness Products sales surged 121% to $1.88 million.
• Total (deficit) equity was $(1.073) million as of September 30, 2025, compared to $7.544 million as of December 31, 2024.

Sentiment

Score: 7

Explanation: The company reported strong revenue growth and improved gross margins, leading to increased full-year guidance. While net loss increased, the adjusted EBITDA net loss showed a slight improvement, and the company has a clear path to positive adjusted EBITDA in 2026. The cash position also improved. The increase in net loss is largely attributed to non-operating items like acquisition-related costs and interest expense, rather than core operational issues.

Positives

• Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3 2024.
• Year-to-date revenue of $22.8 million, a 26% increase compared to the first nine months of 2024.
• Gross margin improved to 86% in Q3 2025 from 84% in Q3 2024.
• Total Cash increased to $13.2 million as of September 30, 2025, from $12.2 million at December 31, 2024.
• Increased full-year 2025 revenue guidance to $31.5 million to $32.5 million.
• Prescription sales, particularly gammaCore and Quell Fibromyalgia in the VA market, showed strong growth.
• Truvaga revenue hit a record high of $1.7 million in the quarter.
• Adjusted EBITDA net loss slightly improved to $2.0 million in Q3 2025 from $2.1 million in Q3 2024.

Negatives

• Net loss increased to $3.4 million in Q3 2025 from $2.5 million in Q3 2024.
• Net loss per share increased to $0.40 in Q3 2025 from $0.31 in Q3 2024.
• Total operating expenses increased to $10.4 million in Q3 2025 from $8.1 million in Q3 2024.
• Selling, general and administrative expense increased by $2.1 million to $9.7 million in Q3 2025.
• Research and development expense increased to $0.7 million in Q3 2025 from $0.5 million in Q3 2024.
• Total other expense was $0.5 million in Q3 2025, primarily due to acquisition-related costs and interest expense, compared to total other income of $0.2 million in Q3 2024.
• Total liabilities increased to $22.485 million as of September 30, 2025, from $12.927 million as of December 31, 2024.
• Total (deficit) equity decreased to $(1.073) million as of September 30, 2025, from $7.544 million as of December 31, 2024.

Risks

• Ability to raise additional funding needed to continue business and product development plans.
• Inherent uncertainties associated with developing new products or technologies.
• Ability to commercialize gammaCore, TAC-STIM, Truvaga, and Quell products.
• Impact of inflation and currency fluctuations.
• Competition in the industry.
• Overall economic and market conditions.

Future Outlook

The company increased its full-year 2025 revenue guidance to $31.5 million to $32.5 million. It expects net cash usage for the fourth quarter of 2025 to be between approximately $2.0 million and $2.5 million. electroCore anticipates reaching $12.0 million in quarterly revenue and achieving its first quarter of positive adjusted EBITDA in the second half of 2026.

Management Comments

• "Prescription sales continued to accelerate in this quarter driven by sales within the department of Veteran Affairs (VA) market."
• "gammaCore and Quell Fibromyalgia each showed strong growth in the VA with gammaCore sales increasing 16% over the same period in 2024 and Quell contributing $530,000 in VA revenues and $595,000 of total product sales in the quarter."
• "With Truvaga revenue also hitting a record high of $1.7 million in the quarter, we are increasing our revenue guidance to $31.5 million to $32.5 million for the full year 2025."
• "For the remainder of 2025, the Company plans on continuing to make targeted investments in sales and marketing to support its commercial efforts."

Industry Context

electroCore operates in the bioelectronic technology and neuromodulation space, focusing on non-invasive vagus nerve stimulation (nVNS) for chronic pain and general wellness. The growth in VA sales for gammaCore and Quell Fibromyalgia indicates successful penetration into government healthcare markets, a key strategy for medical device companies. The strong performance of Truvaga suggests increasing consumer adoption of non-prescription wellness devices, aligning with broader trends in self-care and preventative health.

Comparison to Industry Standards

• NA

Legal Proceedings

• Legal fees associated with stockholders litigation.
• Legal fees associated with intellectual property litigation.

Related Party Transactions

• Interest expense on the convertible debt financing with Avenue Venture Opportunities Fund II, L.P.

Stakeholder Impact

• Shareholders: Positive revenue growth and increased guidance could lead to increased investor confidence. However, increased net loss and negative equity might be a concern. The mention of "stockholders litigation" indicates existing legal issues impacting shareholders.
• Employees: Continued investment in sales and marketing suggests stable or growing employment opportunities in those areas. Increased R&D implies ongoing innovation efforts.
• Customers: Strong sales growth in prescription devices (gammaCore, Quell) and wellness products (Truvaga) indicates increasing customer adoption and satisfaction.
• Creditors: The company has convertible debt financing with Avenue Venture Opportunities Fund II, L.P., and increased total liabilities, which is relevant for creditors.

Next Steps

• Host a conference call and webcast on November 5, 2025, at 4:30 PM EDT.
• Continue targeted investments in sales and marketing for the remainder of 2025 to support commercial efforts.
• Work towards achieving $12.0 million in quarterly revenue and positive adjusted EBITDA in the second half of 2026.

Key Dates

Recommendation

While electroCore demonstrated strong revenue growth and improved gross margins, leading to an upward revision of full-year guidance, the increase in net loss and negative total equity are notable concerns. The company has a clear path to achieving positive adjusted EBITDA in the second half of 2026, which is a positive long-term indicator. However, the current financial position, including increased liabilities and the need for potential future funding, suggests a 'hold' recommendation. Investors should monitor the company's progress towards its profitability targets and its ability to manage its balance sheet effectively before considering a 'buy' or 'sell' position.

Keywords

bioelectronic technology, neuromodulation, gammaCore, Truvaga, Quell Fibromyalgia, n VNS, SEC filing, financial results, Q3 2025, revenue guidance, medical devices, pain management, wellness products, NASDAQ: ECOR